Use of Letermovir as Salvage Therapy for Drug-resistant CMV Retinitis: A Case Series.

Use of Letermovir as Salvage Therapy for Drug-resistant CMV Retinitis: A Case Series.
Antimicrob Agents Chemother. 2019 Jan 14;:
Authors: Turner N, Strand A, Grewal DS, Cox G, Arif S, Baker AW, Maziarz EK, Saullo JH, Wolfe CR
Abstract
Treatment options for drug-resistant CMV are limited. Letermovir is a novel antiviral recently approved for CMV prophylaxis following hematopoietic cell transplantation, but efficacy in other settings is unknown. We recently used letermovir for salvage treatment in four solid organ transplant recipients with ganciclovir-resistant CMV retinitis. All patients improved clinically without known adverse drug events. However, three patients failed to maintain virologic suppression, including two patients who developed genotypically-confirmed resistance to letermovir while on therapy.
PMID: 30642941 [PubMed - as supplied by publisher]

Source: Antimicrobial Agents and Chemotherapy - January 14, 2019 Category: Microbiology Authors: Turner N, Strand A, Grewal DS, Cox G, Arif S, Baker AW, Maziarz EK, Saullo JH, Wolfe CR Tags: Antimicrob Agents Chemother Source Type: research